Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
Novartis
AstraZeneca
Amgen
Eli Lilly and Company
Astellas Pharma Inc
PharmaMar
Rezolute
AstraZeneca
Telix Pharmaceuticals (Innovations) Pty Limited
Quetzal Therapeutics
Bayer
AbbVie
Curtin University
Hoffmann-La Roche
Karyopharm Therapeutics Inc
Alume Biosciences, Inc.
Hoffmann-La Roche
Genmab
NaviFUS Corporation
Regeneron Pharmaceuticals
BriaCell Therapeutics Corporation
University of Utah
Hoffmann-La Roche
AstraZeneca
Resilience
Astellas Pharma Inc
Amgen
Imperial College London
Acerta Pharma BV
Almirall, S.A.
Regeneron Pharmaceuticals
AbbVie
AbbVie
Protara Therapeutics
Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc.
University Hospital, Strasbourg, France
Relmada Therapeutics, Inc.
Amgen
Hoffmann-La Roche
GT Medical Technologies, Inc.
Peter MacCallum Cancer Centre, Australia
AstraZeneca
Pfizer
Oslo University Hospital
AbbVie
Hoffmann-La Roche
Institut Paoli-Calmettes